> Detailanzeige
Griessbach, Alexandra;
Chammartin, Frédérique;
Abela, Irene A;
Amico, Patrizia;
Stoeckle, Marcel P;
Eichenberger, Anna L;
Hasse, Barbara;
Braun, Dominique L;
Schuurmans, Macé M;
Müller, Thomas F;
Tamm, Michael;
Audigé, Annette;
Mueller, Nicolas J;
Rauch, Andri;
Günthard, Huldrych F;
Koller, Michael T;
Trkola, Alexandra;
Epp, Selina;
Amstutz, Alain;
Schönenberger, Christof M;
Taji Heravi, Ala;
Kusejko, Katharina;
Bucher, Heiner C;
Briel, Matthias;
[...]
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
- Beteiligte: Griessbach, Alexandra; Chammartin, Frédérique; Abela, Irene A; Amico, Patrizia; Stoeckle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Audigé, Annette; Mueller, Nicolas J; Rauch, Andri; Günthard, Huldrych F; Koller, Michael T; Trkola, Alexandra; Epp, Selina; Amstutz, Alain; Schönenberger, Christof M; Taji Heravi, Ala; Kusejko, Katharina; Bucher, Heiner C; Briel, Matthias; [...]
-
Erschienen:
Oxford University Press (OUP), 2023
- Erschienen in: Open Forum Infectious Diseases, 10 (2023) 4
- Sprache: Englisch
- DOI: 10.1093/ofid/ofad150
- ISSN: 2328-8957
- Entstehung:
- Anmerkungen:
- Beschreibung: AbstractExtension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%–100.0%]) in individuals with different levels of immunosuppression (difference, −2.8% [95% CI, −6.8% to 1.3%]).
- Zugangsstatus: Freier Zugang